Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In recognition of the new links with the Nuffield Department of Clinical Neurosciences and the Department of Experimental Psychology, the Oxford Clinical Trials Unit for Mental Illness (OCTUMI) has a new name: the Oxford Cognitive Health and Neuroscience Clinical Trials Unit (OCHNCTU, pronounced oc-n-tü) and a new logo.

The OCHNCTU portfolio will, in future, include trials for neurological conditions and cognitive neuroscience. The CTU offers advice and support in all aspects of the planning, conducting and reporting of clinical trials. Key areas of expertise include statistics, trial management, quality assurance, database provision and data management. Where resources permit, specific services (such as a randomisation program or trial monitoring) can be provided.

 

OCHNCTU projects include both non-commercial efficacy trials designed to reduce the uncertainties associated with current treatments and early phase trials evaluating potential new treatments. The CTU is working closely with the Oxford NHS Trusts to increase research productivity and recruitment into trials and has links with TVCLRN, DeNDRoN, the MHRN and other Oxford University Clinical Trials Units. OCHNCTU is also closely affiliated to the Oxford Cognitive Health Clinical Research Facility which supports the translation of neuroscience discoveries into effective therapies. 

For more information, contact Dr Jennifer Rendell on 01865 226465, email ochnctu@psych.ox.ac.uk

Similar stories

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.

Emerging Leaders Prize celebrates outstanding pain researchers

Award Clinical Neurology

2020’s Emerging Leaders Prize awards £200,000 to outstanding scientists from the University of Oxford, University College London and King’s College London, who are all working in the field of pain research.

MRC New Investigator Award for John Dawes

Clinical Neurology Research

Neuropathic pain arises from disease or damage of the nervous system. It is a major clinical problem affecting 5-10% of the adult population, despite the use of current therapies.